Unlike other predictive biomarkers, such as, e.g., PD-L1 with a required TPS of 50% for therapy of NSCLC with Pembrolizumab, so far, a high (≥50%) DLL3 expression of SCLC is not implemented as a prerequisite for therapy with Rova-T. This evidence concerns the gene DLL3 and small cell lung carcinoma.